ArticleWorld journal of gastroenterology2015
Fecal transplant policy and legislation.
Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Gut Microbiota Dysbiosis in Preeclampsia: Mechanisms, Biomarkers, and Probiotic-Based Interventions.Mediators of inflammation · 2025Article
- Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond.SAGE open medicine · 2024Review
- In Vitro and In Vivo Anti-Journal of microbiology and biotechnology · 2022Article
- Bibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021.Frontiers in cellular and infection microbiology · 2022Article
- A probiotic yeast-based immunotherapy againstScience translational medicine · 2020Article
- Problems with the concept of gut microbiota dysbiosis.Microbial biotechnology · 2020Review
- Faecal microbiota transplantation: a regulatory hurdle?BMC gastroenterology · 2017Review
- Faecal microbiota transplantation in patients withWorld journal of gastroenterology · 2017Article
- Oral microbiota transplant: a potential new therapy for oral diseases.Journal of the California Dental Association · 2017Article
- Transmission of the gut microbiota: spreading of health.Nature reviews. Microbiology · 2017Review
- Treatment With Fecal Microbiota Transplantation: The Need for Complete Methodological Reporting for Clinical Trials.Annals of internal medicine · 2017Article
- Consensus report: faecal microbiota transfer - clinical applications and procedures.Alimentary pharmacology & therapeutics · 2017Review
- Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.Clinical microbiology reviews · 2017Review
- Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity.EBioMedicine · 2016Review
- Biome engineering-2020.Microbial biotechnology · 2016Review
- Environmental management in the gut: fecal transplantation to restore the intestinal ecosystem.Infectious diseases (London, England) · 2016Article
- Early Results of Fecal Microbial Transplantation Protocol Implementation at a Community-based University Hospital.Journal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fecal microbiota transplantation (FMT) has garnered significant attention in recent years in the face of a reemerging Clostridium difficile (C. difficile) epidemic. Positive results from the first randomized control trial evaluating FMT have encouraged the medical community to explore the process further and expand its application beyond C. difficile infections and even the gastrointestinal domain. However promising and numerous the prospects of FMT appear, the method remains limited in scope today due to several important barriers, most notably a poorly defined federal regulatory policy. The Food and Drug Administration has found it difficult to standardize and regulate the administration of inherently variable, metabolically active, and ubiquitously available fecal material. The current cumbersome policy, which classifies human feces as a drug, has prevented physicians from providing FMT and deserving patients from accessing FMT in a timely fashion, and subsequent modifications seem only to be temporary. The argument for reclassifying fecal material as human tissue is well supported. Essentially, this would allow for a regulatory framework that is sufficiently flexible to expand access to care and facilitate research, but also appropriately restrictive and centralized to ensure patient safety. Such an approach can facilitate the advancement of FMT to a more refined, controlled, and aesthetic process, perhaps in the form of a customized and well-characterized stool substitute therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.